Pseudoarylsulfatase-A Deficiency in the Neurologically Impaired Patient

Kevin Farrell, D.A. Applegarth, J.R. Toone, P.M. McLeod, and A.V. Savage

ABSTRACT: The demonstration of low arylsulfatase-A (ASA) activity in leucocytes or fibroblasts is used often to establish the diagnosis of metachromatic leucodystrophy (MLD). However, low ASA activity is observed also in pseudo-ASA deficiency which may be as common as MLD. We report two patients with pseudo ASA deficiency who had abnormal neurological findings consistent with atypical MLD. Because the measurement of ASA activity is neither a sensitive nor specific method with which to establish a diagnosis of MLD, this diagnosis should be confirmed by nerve biopsy, measurement of urinary sulfatide or a cerebroside sulfate loading test, using cultured fibroblasts.

RÉSUMÉ: La déficience en arylsulfatase chez le patient atteint neurologiquement La démonstration d’une activité basse en arylsulfatase — A (ASA) dans les leucocytes ou les fibroblastes sert souvent dans le diagnostic de la leucodystrophie métachromatique (MLD). Cependant, une activité ASA basse est également observée dans la pseudo-déficience ASA qui est peut-être aussi fréquente que le MLD. Nous faisons rapport sur deux patients avec pseudo-déficience ASA dont le tableau neurologique était proche de celui du MLD. Puisque la mesure de l’activité ASA est peu sensible et peu spécifique, le diagnostic du MLD devrait toujours être confirmé par une biopsie neurale, la mesure des sulfatides urinaires ou un test de surcharge en cérébroside sulfate sur des fibroblastes en culture.

Metachromatic leucodystrophy (MLD) is a progressive, neurodegenerative disease characterised by demyelination and deposition of metachromatic granules in the central and peripheral white matter.\(^1\) Deficiency of arylsulfatase A (ASA) impairs the metabolism of cerebroside sulfate and has been demonstrated in patients with MLD.\(^1\) The ability to measure ASA activity in leucocytes and fibroblasts has simplified the diagnosis. However, deficiency of ASA activity, per se, is not necessarily diagnostic of MLD. Thus, low ASA activity has been reported in healthy relatives of MLD patients, and in other normal individuals with no family history of MLD.\(^2\) This finding has been termed pseudo-ASA deficiency. Because pseudo-ASA deficiency may occur in patients with other neurological disorders, there is a potential for misdiagnosis.\(^3,4\) We describe two such patients, the methods used to establish that they did not have MLD and discuss a possible relationship between pseudo-ASA deficiency and neurological disease.

CASE REPORTS

Case 1: A female infant was born at term by vertex vaginal delivery following a normal pregnancy. The Apgar scores were 9 and 10 at one and five minutes respectively. There was no family history of neurological disease. Length, weight and head circumference were at the 50th percentiles. Examination at birth was normal but repeated suctioning of tracheal and oral secretions was required in the first week. Extensor posturing was observed at two weeks and fisting at ten weeks of age. At five months of age, height and weight were at the 25th percentile. However, the head circumference was at the 3rd percentile. The infant was visually attentive and had a brisk acoustic startle. Cranial nerve examination was normal. Head control was poor and there was spasticity involving the arms more than legs and brisk deep tendon reflexes. Tonic seizures occurred at six months of age and by three years there were intractable seizures. At this time irritability was more pronounced but she was visually alert and could eye point to many different named objects. There was marked truncal hypotonia with athetoid posturing and increased tone in all limbs.

CT-scan at five months of age showed decreased attenuation in periventricular white matter, particularly around the occipital horns. The ASA level was below the normal range (Table 1). CSF protein was 1.8 g/L. Nerve conduction velocities were normal in both motor (41 m/sec) and sensory (39 m/sec) fibres of the median nerve and in the motor fibres (47 m/sec) of the lateral popliteal nerve. Sural nerve biopsy at nine months of age demonstrated no evidence of demyelination or metachromasia. ASA levels in the parents were in the MLD heterozygote range, while those of the normal older sibling were below the normal range (Table 1). Cerebroside sulfate loading tests of the fibroblasts from the proband and sibling showed that they had normal ability to degrade cerebroside sulfate. (Fig 1). Assays for plasma ammonia, amino acids, long chain fatty acids, urinary amino acids, urinary organic acids, leucocyte galactocerebrosidase and serological studies for toxoplasma, rubella, cytomegalovirus and herpes simplex were normal. A second CT scan repeated at 24 months of age showed poorly developed...
Table 1: Aryl Sylphatase A (nmoles/hr/mg protein)

<table>
<thead>
<tr>
<th></th>
<th>Leucocytes</th>
<th>Fibroblasts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient 1</strong></td>
<td>19.6</td>
<td>33.3</td>
</tr>
<tr>
<td><strong>Mother of patient 1</strong></td>
<td>38</td>
<td></td>
</tr>
<tr>
<td><strong>Father of patient 1</strong></td>
<td>34.4</td>
<td>186.5</td>
</tr>
<tr>
<td><strong>Sister of patient 1</strong></td>
<td>17.6</td>
<td>46.4</td>
</tr>
<tr>
<td><strong>Patient 2</strong></td>
<td>9.4</td>
<td>12.7</td>
</tr>
<tr>
<td><strong>Mother of patient 2</strong></td>
<td>85.9</td>
<td></td>
</tr>
<tr>
<td><strong>Patient with MLD New Jersey Cell Bank GM 243</strong></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Controls run in the same assay</td>
<td>mean (9) 156.4</td>
<td>370.5</td>
</tr>
<tr>
<td></td>
<td>range 99.9 - 297.5</td>
<td>213.8</td>
</tr>
</tbody>
</table>

Established control range (n 30)  
mean 109  
range 51-215

Cortical sulci and abnormal differentiation of grey and white matter. This suggested the possibility that the patient had a cerebral dysgenesis.

Case 2: A male infant was born at term following a normal pregnancy. He did not require to be resuscitated. He was of normal weight and no abnormality was noted in the neonatal period. There was no family history of neurological disease. Intractable seizures developed at four months of age. The patient walked at three years, was able to say a few words by five years and at six years his Developmental Quotient was 24 on the Cattell Scale. At sixteen years the gait was broad-based and he had regressed mentally. There was mild hypotonia, the deep tendon reflexes were hyporeactive, and plantar responses were downgoing. CSF protein at this time was 0.6 g/L and the colloidal gold curve was 23440.

Motor and sensory median nerve conduction and lateral popliteal motor nerve conduction were normal. Over the next two years there was further mental deterioration and the ability to walk was lost. The ASA level in fibroblasts was 10% of normal value. On this basis, a diagnosis of atypical metachromatic leucodystrophy was made. The patient was reassessed at 26 years of age when his sisters sought genetic counselling. At this time the patient was confined to bed and unresponsive to command, but would withdraw from pinprick. There were orofacial dyskinesias and dystonic posturing of upper limbs. Tone was increased in the upper limbs and decreased in the lower limbs. The tendon reflexes were brisk in the arms and decreased in the legs. The plantar responses were flexor. ASA levels were in the MLD homozygote range (Table 1). However, the cerebroside sulphate loading test demonstrated normal fibroblast function (Fig 1). Posterior tibial motor nerve conduction and superficial peroneal sensory nerve conduction were normal. Sural nerve biopsy showed a decrease in the number of large fibres. Electron microscopy showed no evidence of demyelination or inclusions. CT scan showed minimal dilatation of the lateral ventricles and prominent sulci. Assays for alpha and beta N-acetyl hexosaminidase, beta-galactosidase, acid phosphatase, beta-glucosidase, alpha-glucosidase, alpha-mannosidase, and alpha-fucosidase in leucocytes and fibroblasts yielded normal results.

**LABORATORY METHODS**

Leukocytes from 3 ml heparinised venous blood were isolated by sedimentation in 6% dextran and stored at −20°C prior to assay. Cells were disrupted by sonication and the supernatant used for assay of ASA. Cultured skin fibroblasts were grown in Eagles essential medium + 12.5% fetal calf serum. When confluent, the fibroblasts were harvested by trypsinisation and the pellets stored at −70°C prior to assay. Cells were disrupted by three cycles of freeze-thawing and the whole homogenate used for assay of ASA activity. Galactocerebrosidase activity was assayed by the method of Suzuki. All other lysosomal enzyme assays were by conventional 4-methyl umbelliferyl fluorometric or spectrophotometric methods.

The cerebroside sulphate loading test was carried out by a modification of the method of Kihara using 3H-cerebroside sulphate labelled in the fatty acid moiety (provided by Dr. D. Farrell, Seattle). For each experiment two negative controls and one positive MLD cell line (Human Genetic Mutant Cell Repository GM 243 - designated NJCB GM 243 in figure 1) were grown with the patients. Patients 1 and 2 and the sister of...
patient 1 were tested. Unlabelled cerebroside sulphate (Supelco, Inc. Bellafonte, PA) and 3H-cerebroside sulphate were dispersed in Eagles MEM + 12.5%FCS to give a final concentration of 0.024mM and 3.5x10⁴ counts/min/ml. Cultures in 6 T25 flasks per cell line were initiated and after two days growth the medium was replaced by 4 ml of the labelled cerebroside sulphate medium. Duplicate flasks were harvested by trypsinisation and scraping at 2, 4 and 6 days incubation and the washed cell pellets were lyophilised. Cells were extracted and cerebroside sulphate separated from cerebroside by DE 52 chromatography following the method of Poulos and Beckman.9 The cellular debris left after extraction was dissolved in 0.1 ml 2.5N NaOH. The solution was neutralised and assayed for protein by the method of Lowry.10

**Discussion**

Cerebroside sulfate is metabolised by the combined action of heat-labile ASA and a heat-stable nonenzymatic protein activator. Most cases of MLD are due to a deficiency of ASA activity. However, some patients with MLD have ASA activity in the normal or heterozygous range. These patients have been shown to have either a deficiency of cerebroside sulfatase activator protein11,12 or a Km mutant of ASA13 (Km, the Michaelis constant, is a parameter of enzyme function). Thus MLD may occur occasionally in the presence of normal ASA activity. A more common diagnostic dilemma is the occurrence of ASA activity in the homozygote range in a patient without MLD.2 Fibroblasts from such an individual hydrolyse sulfatide at a normal rate and this phenotype has been termed pseudo-ASA deficiency.2 Langenbeck has proposed that pseudo-ASA deficiency is due to a mutation at the ASA locus resulting in an allele which codes for ASA which has low activity in vitro.14 Because the frequency of the pseudo-deficiency allele may be equal to or higher than the frequency of the ASA deficiency allele,15,16 low ASA activity may be associated with pseudo-ASA deficiency as frequently as with MLD.1

The two patients reported in this paper had features which led us to measure ASA activity and conclude initially that they might have MLD. Although patient 1 had a static encephalopathy with onset in the neonatal period, the motor system was the most severely involved. A congenital form of MLD has been proposed17,18 and the early CT scan changes were similar to those which have been described in metachromatic leucodystrophy.19 The second patient had a progressive neurological problem and the finding of low ASA activity led to the misdiagnosis of MLD.

Although pseudo-ASA deficiency was described initially in normal relatives of patients with MLD, it has been reported subsequently in neurologically abnormal patients with no family history of MLD.1,3,4 Indeed, a previously described “atypical variant of MLD” may well have had this combination of pseudo ASA deficiency and a non-MLD neurologic disease.20 The relationship between the pseudo-ASA deficiency and the neurological dysfunction in these patients may be coincidental. The healthy sibling of patient 1 and a healthy sibling of one of the previously reported cases also had low ASA activity.1 However, Dubois showed that a group of patients with non-MLD neurologic diseases had significantly lower ASA levels than control patients.21 In addition, Peiffer described a boy in whom the enzyme levels suggested that he might be a compound heterozygote of MLD and pseudo-ASA deficiency.22 In that child, the neuropathological examination of the brain showed a diffuse cerebral sclerosis without the features of MLD. Thus it is possible that pseudo-ASA deficiency may confer an increased risk of a demyelinating or other neurological disorder.

The relatively high incidence of pseudo-ASA deficiency together with the genetic and prognostic implications of MLD emphasize the importance of using a more definitive method to establish the diagnosis of MLD. The cerebroside sulfate loading test can be used to establish the diagnosis of MLD even in the presymptomatic patient or fetus.23 Thus cultured fibroblasts from patients with MLD develop metachromatic granules when grown in a medium supplemented with exogenous cerebroside sulfate. This has not been reported in fibroblasts from obligate heterozygotes, controls or patients with pseudo ASA deficiency.2 In addition, the cerebroside sulfate loading test has been shown to discriminate between amniotic fluid cells from fetuses with pseudo-ASA deficiency and MLD.8

Nerve biopsy is another sensitive and specific method of confirming the diagnosis of MLD.23 Although nerve biopsy is an invasive investigation, it can be performed in most centres, whereas the cerebroside sulfate loading test can be done only in a few laboratories. Demonstration of an increased amount of sulfatide in urine can also be used to confirm the diagnosis of MLD.1 However, this test is available in relatively few laboratories.

**Acknowledgements**

We wish to thank Dr. B. P. DeJong for permission to report patient 1.

**References**


